<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196283</url>
  </required_header>
  <id_info>
    <org_study_id>M19-894</org_study_id>
    <secondary_id>2019-003167-22</secondary_id>
    <nct_id>NCT04196283</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Subjects With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Idera Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK)
      of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368
      plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic
      (R/M) head and neck squamous cell carcinoma (HNSCC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">May 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 16, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of ABBV-368</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Maximum Serum Concentration (Cmax) of ABBV-368</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Serum Concentration (Tmax) of ABBV-368</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Time to Maximum Serum Concentration (Tmax) of ABBV-368</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Serum Concentration-Time Curve of ABBV-368 From Time 0 to the Time of Last Measurable Concentration (AUCt)</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Area Under Serum Concentration-Time Curve of ABBV-368 From Time 0 to the Time of Last Measurable Concentration (AUCt)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal-Phase Elimination Rate Constant (β) of ABBV-368</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Terminal-Phase Elimination Rate Constant (β) of ABBV-368</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-Life (t1/2) of ABBV-368</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Terminal Half-Life (t1/2) of ABBV-368</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Tilsotolimod</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Maximum Observed Plasma Concentration (Cmax) of Tilsotolimod</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax) of Tilsotolimod</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Time to Maximum Plasma Concentration (Tmax) of Tilsotolimod</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Plasma Concentration-Time Curve of Tilsotolimod From Time 0 to the Time of Last Measurable Concentration (AUCt)</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Area Under Plasma Concentration-Time Curve of Tilsotolimod From Time 0 to the Time of Last Measurable Concentration (AUCt)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal-Phase Elimination Rate Constant (β) of Tilsotolimod</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Terminal-Phase Elimination Rate Constant (β) of Tilsotolimod</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-Life (t1/2) of Tilsotolimod</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Terminal Half-Life (t1/2) of Tilsotolimod</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of ABBV-181 (Arm 3 Only)</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Maximum Observed Serum Concentration (Cmax) of ABBV-181</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Serum Concentration (Tmax) of ABBV-181 (Arm 3 Only)</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Time to Maximum Serum Concentration (Tmax) of ABBV-181</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under Serum Concentration-Time Curve of ABBV-181 From Time 0 to the Time of Last Measurable Concentration (AUCt) (Arm 3 Only)</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Area Under Serum Concentration-Time Curve of ABBV-181 From Time 0 to the Time of Last Measurable Concentration (AUCt)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal-Phase Elimination Rate Constant (β) of ABBV-181 (Arm 3 Only)</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Terminal-Phase Elimination Rate Constant (β) of ABBV-181</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Half-Life (t1/2) of ABBV-181 (Arm 3 Only)</measure>
    <time_frame>Cycle 1 through Cycle 3 (each cycle is approximately 28 days)</time_frame>
    <description>Terminal Half-Life (t1/2) of ABBV-181</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to approximately 2 years following the first dose</time_frame>
    <description>ORR is measured as the percentage of participants with a complete response (CR) or partial response (PR) as a confirmed response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Up to approximately 2 years following the first dose</time_frame>
    <description>CBR is measured as the percentage of participants with a confirmed complete response (CR), confirmed partial response (PR), or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Up to approximately 2 years following the first dose</time_frame>
    <description>TTR is the time from date of first study drug exposure to the first instance of a complete response (CR) or partial response (PR) as a confirmed response, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to approximately 2 years following the first dose</time_frame>
    <description>PFS is the time from date of first study drug exposure to disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to approximately 2 years following the first dose</time_frame>
    <description>DOR is the time from the participant's initial response (CR or PR as a confirmed response) to disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Advanced Solid Tumors Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: ABBV-368 + Tilsotolimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered ABBV-368 and Tilsotolimod at various timepoints as described in the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: ABBV-368 + Tilsotolimod + Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered ABBV-368, Tilsotolimod and Nab-paclitaxel at various timepoints as described in the protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: ABBV-368 + Tilsotolimod + Nab-paclitaxel + ABBV-181</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered ABBV-368, Tilsotolimod, Nab-paclitaxel and ABBV-181 at various timepoints as described in the protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-368</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Arm 1: ABBV-368 + Tilsotolimod</arm_group_label>
    <arm_group_label>Arm 2: ABBV-368 + Tilsotolimod + Nab-paclitaxel</arm_group_label>
    <arm_group_label>Arm 3: ABBV-368 + Tilsotolimod + Nab-paclitaxel + ABBV-181</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tilsotolimod</intervention_name>
    <description>Intratumoral (IT) injection</description>
    <arm_group_label>Arm 1: ABBV-368 + Tilsotolimod</arm_group_label>
    <arm_group_label>Arm 2: ABBV-368 + Tilsotolimod + Nab-paclitaxel</arm_group_label>
    <arm_group_label>Arm 3: ABBV-368 + Tilsotolimod + Nab-paclitaxel + ABBV-181</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Arm 2: ABBV-368 + Tilsotolimod + Nab-paclitaxel</arm_group_label>
    <arm_group_label>Arm 3: ABBV-368 + Tilsotolimod + Nab-paclitaxel + ABBV-181</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-181</intervention_name>
    <description>Intravenous (IV) infusion</description>
    <arm_group_label>Arm 3: ABBV-368 + Tilsotolimod + Nab-paclitaxel + ABBV-181</arm_group_label>
    <other_name>Budigalimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants should weigh at least 35 kg.

          -  Eastern Cooperative Oncology Group performance status of 0 or 1 and a life expectancy
             of &gt;= 3 months.

          -  Participant have &gt;= 1 lesion accessible for intratumoral injection.

          -  Histologically or cytologically confirmed R/M HNSCC (of the following 4 subsites: oral
             cavity, oropharynx, larynx, and hypopharynx) who previously progressed either during
             or after &lt;= 3 prior treatment regimens administered in the recurrent or metastatic
             setting.

          -  Must have received 1 immunotherapy regimen which included a PD-(L)1 inhibitor.

        Exclusion Criteria:

          -  Uncontrolled metastases to the central nervous system (CNS).

               -  Participants with brain metastases are eligible provided that evidence of
                  clinical and radiographic stable disease for at least 4 weeks after definitive
                  therapy is given and participants have not used prohibited levels of steroids for
                  at least 4 weeks prior to first dose of the study.

          -  Received prior treatment with OX40 or toll-like receptor (TLR) agonists (excluding
             topical agents).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSD Moores Cancer Center - LaJolla /ID# 216181</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago /ID# 217196</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute /ID# 216179</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241-2832</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute /ID# 214050</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital /ID# 215786</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System /ID# 216159</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960-6136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center /ID# 215882</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Med Ctr /ID# 214040</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center /ID# 214041</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Curie /ID# 215653</name>
      <address>
        <city>Paris CEDEX 05</city>
        <state>Ile-de-France</state>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy /ID# 215865</name>
      <address>
        <city>Villejuif</city>
        <state>Ile-de-France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone /ID# 215657</name>
      <address>
        <city>Marseille CEDEX 05</city>
        <state>Provence-Alpes-Cote-d Azur</state>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Andre /ID# 215702</name>
      <address>
        <city>Bordeaux</city>
        <zip>33800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne /ID# 215706</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Erlangen /ID# 214196</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Leipzig /ID# 214200</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charite-Univ. Berlin, Benjamin-Franklin /ID# 214197</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center /ID# 215230</name>
      <address>
        <city>Petakh Tikva</city>
        <state>Tel-Aviv</state>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus /ID# 215231</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital /ID# 215862</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center /ID# 215229</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5239424</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek /ID# 215291</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona /ID# 214264</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICO l´Hosp- Hosp Duran Reynals /ID# 221402</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Univ de Fuenlabrada /ID# 214263</name>
      <address>
        <city>Fuenlabrada</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Univ 12 de Octubre /ID# 214198</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Univ Madrid Sanchinarro /ID# 214110</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Uni Virgen de la Victoria /ID# 214109</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Clin Univ de Valencia /ID# 221401</name>
      <address>
        <city>València</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>December 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>June 30, 2020</last_update_submitted>
  <last_update_submitted_qc>June 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Squamous Cell Carcinoma</keyword>
  <keyword>Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Locally Advanced Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Metastatic Head and Neck Squamous Cell Carcinoma</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

